Exchange: NASDAQ·Updated 04:12 AM EDT
RLMD logo

RLMD Relmada Therapeutics Inc

$4.50
$0.13
(2.98%)
Pre-Market
Prev Close $4.37
Reported EarningsAug 6
Mkt Cap$484.28M
Vol17.00

About RLMD

Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
52

Neutral Sentiment

How do you feel about RLMD?

Advertisement|Remove ads.